Literature DB >> 22238162

Plasma HIV-1 RNA levels during antiretroviral therapy: how low is low enough?

Rajesh T Gandhi, Steven G Deeks.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22238162      PMCID： PMC3275763          DOI： 10.1093/cid/cir933

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  14 in total

Review 1.  The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs.

Authors:  J S Murray; M R Elashoff; L C Iacono-Connors; T A Cvetkovich; K A Struble
Journal:  AIDS       Date:  1999-05-07       Impact factor: 4.177

2.  Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy.

Authors:  Tomas Doyle; Colette Smith; Paola Vitiello; Valentina Cambiano; Margaret Johnson; Andrew Owen; Andrew N Phillips; Anna Maria Geretti
Journal:  Clin Infect Dis       Date:  2012-01-11       Impact factor: 9.079

3.  Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level.

Authors:  Viviane D Lima; David R Bangsberg; P Richard Harrigan; Steven G Deeks; Benita Yip; Robert S Hogg; Julio S G Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

4.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

5.  Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice.

Authors:  Richard D Moore; John G Bartlett
Journal:  Clin Infect Dis       Date:  2011-08-14       Impact factor: 9.079

6.  Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

Authors:  D McMahon; J Jones; A Wiegand; S J Gange; M Kearney; S Palmer; S McNulty; J A Metcalf; E Acosta; C Rehm; J M Coffin; J W Mellors; F Maldarelli
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

7.  A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

Authors:  Hiroyu Hatano; Timothy L Hayes; Viktor Dahl; Elizabeth Sinclair; Tzong-Hae Lee; Rebecca Hoh; Harry Lampiris; Peter W Hunt; Sarah Palmer; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Barbara L Shacklett; Steven G Deeks
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

8.  Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.

Authors:  Diane V Havlir; Matthew C Strain; Mario Clerici; Caroline Ignacio; Daria Trabattoni; Pasquale Ferrante; Joseph K Wong
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection.

Authors:  Vikram S Gill; Viviane D Lima; Wen Zhang; Brian Wynhoven; Benita Yip; Robert S Hogg; Julio S G Montaner; P Richard Harrigan
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

10.  The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

Authors:  Rajesh T Gandhi; Lu Zheng; Ronald J Bosch; Ellen S Chan; David M Margolis; Sarah Read; Beatrice Kallungal; Sarah Palmer; Kathy Medvik; Michael M Lederman; Nadia Alatrakchi; Jeffrey M Jacobson; Ann Wiegand; Mary Kearney; John M Coffin; John W Mellors; Joseph J Eron
Journal:  PLoS Med       Date:  2010-08-10       Impact factor: 11.069
View more
  7 in total

1.  Lack of correlation between reaction speed and analytical sensitivity in isothermal amplification reveals the value of digital methods for optimization: validation using digital real-time RT-LAMP.

Authors:  Eugenia M Khorosheva; Mikhail A Karymov; David A Selck; Rustem F Ismagilov
Journal:  Nucleic Acids Res       Date:  2015-09-10       Impact factor: 16.971

2.  HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.

Authors:  Luke C Swenson; Jeong Eun Min; Conan K Woods; Eric Cai; Jonathan Z Li; Julio S G Montaner; P Richard Harrigan; Alejandro Gonzalez-Serna
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

3.  Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms.

Authors:  Marcel O Bonn-Miller; Megan L Oser; Meggan M Bucossi; Jodie A Trafton
Journal:  J Behav Med       Date:  2012-10-07

4.  A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.

Authors:  Matteo Vassallo; R Fabre; J Durant; C Lebrun-Frenay; H Joly; M Ticchioni; F DeSalvador; A Harvey-Langton; B Dunais; M Laffon; J Cottalorda; P Dellamonica; C Pradier
Journal:  J Neurovirol       Date:  2016-11-04       Impact factor: 2.643

5.  Clinical evaluation of a low cost, in-house developed real-time RT-PCR human immunodeficiency virus type 1 (HIV-1) quantitation assay for HIV-1 infected patients.

Authors:  Palvinder Kaur; Wei Xin Khong; Sue Yuen Wee; Eng Lee Tan; Juergen Pipper; Evelyn Koay; Kah Ying Ng; Joe Kwan Yap; Kuan Kiat Chew; Mei Ting Tan; Yee Sin Leo; Masafumi Inoue; Oon Tek Ng
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

6.  Reduced adherence to antiretroviral therapy is associated with residual low-level viremia.

Authors:  Franco Maggiolo; Elisa Di Filippo; Laura Comi; Annapaola Callegaro; Giorgio L Colombo; Sergio Di Matteo; Daniela Valsecchi; Marco Rizzi
Journal:  Pragmat Obs Res       Date:  2017-05-26

7.  Avoidable workload of care for patients living with HIV infection in Abidjan, Côte d'Ivoire: A cross-sectional study.

Authors:  Viet-Thi Tran; Mariam Mama Djima; Eugene Messou; Jocelyne Moisan; Jean-Pierre Grégoire; Didier K Ekouevi
Journal:  PLoS One       Date:  2018-08-24       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.